Skip to main
  1. Stocks
  2. ARS Pharmaceuticals Inc
  3. Forecast
SPRY

SPRY Stock Forecast & Price Target

SPRY Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ARS Pharmaceuticals is attractive because neffy is the first no-needle intranasal epinephrine product in the U.S. and Europe, addressing a large, growing, underserved anaphylaxis market where autoinjectors remain cumbersome, painful, and inconvenient. Management’s more disciplined launch strategy, broader payer/access work, and targeted physician engagement are already showing traction, with U.S. market share rising to 5% from 4% in 3Q25 and share in salesforce-covered accounts increasing to ~9% from ~6% a year ago. The investment case is further strengthened by ARS-2, which targets a sizeable CSU market with limited competition and meaningful pricing power, while 2026 OpEx was lowered to ~$248M and cash-flow breakeven by 2027 was reaffirmed.

Bears say

ARS Pharmaceuticals is facing a fundamental commercialization challenge because neffy’s $33.4M in 3Q sales fell short of the $38M estimate and $39M consensus, suggesting launch momentum is weaker than expected and inventory fluctuations may be masking uneven demand. Adoption has been slower in a broad, fragmented market with an entrenched low-cost standard of care, while no new July 1 formulary additions or coverage decisions removed a key near-term catalyst for uptake. Reimbursement and access remain major headwinds, as patient cost-sharing, payer resistance to a higher-priced lower-dose product, and likely slow adoption among dermatologists could continue to constrain growth and keep sentiment negative.

SPRY has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ARS Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

SPRY Analyst Forecast & Price Prediction

Get the latest SPRY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SPRY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ARS Pharmaceuticals Inc (SPRY) Forecast

Analysts have given SPRY a Buy based on their latest research and market trends.

According to 3 analysts, SPRY has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ARS Pharmaceuticals Inc (SPRY)


SPRY Analyst Forecast & Price Prediction

Get the latest SPRY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SPRY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SPRY stock data and trends